The 2019 Lyfebulb-Helsinn Innovation Award

Celgene will host Addressing Unmet Needs in MS: An Innovation Challenge,
Summit, NJ
June 12 & 13, 2019


March 18, 2019
Introductory meetings and activities
March 19, 2019
Pitch presentations, gala dinner and award winner announcement

The Winner

UE LifeSciences Inc.

Mihir is passionate about addressing global health disparities with rapid commercialization of scientific discoveries and innovation. After seeing his mother-in-law go through breast cancer, he founded UE LifeSciences to enable affordable and scalable access to early diagnosis of cancer, for women everywhere. UE LifeSciences has developed the iBreastExam, a US FDA-cleared, hand-held device that enables health workers to identify non-palpable breast lumps in just a few minutes, without pain or radiation and at a fraction of the cost of a mammogram. After multiple regulatory approvals, over 200,000 women in 12 countries have benefited, many receiving a breast exam for the first time in their life. With over 15 years of dedicated med-tech commercialization experience, Mihir is leading a multidisciplinary team of clinicians, engineers, and scientists to build meaningful, practical and highly scalable innovations as a defense against the rising tide of cancer globally. Mihir is a two-time TED speaker and adjunct faculty at Drexel University’s School of Biomedical Engineering.

Mihir Shah
CEO and Founder


Ten finalists will compete at the second annual Lyfebulb-Helsinn Innovation Summit. The second annual Lyfebulb-Helsinn Innovation Award will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize creative ideas to better manage cancer using drugs, medical devices or healthcare information technology.


Honorable Mention

Genenta Science

Pierluigi is co-founder and Chairman & CEO at Genenta Science, a clinical stage immune-gene therapy company, and a spinoff from Prof. Luigi Naldini and San Raffaele Milano, which has raised $20M in two rounds. Currently, the company has phase 1/2 trials ongoing in multiple myeloma and glioblastoma. Genenta has labs and an office in Milano and an office at Alexandria Center LaunchLabs, New York.

Pierluigi is a serial entrepreneur and investor in biotech, for example he invested in Ethical Oncology Science (EOS), a company acquired by Clovis Oncology (Nasdaq: CVLS) for $470M in 2013. He is a co-founder and Board Member at Altheia Science, an autoimmune diseases startup that raised $20M for its Series A round in 2018.

Regarding his personal experience, Pierluigi says, “I’m not a scientist, I’m an entrepreneur in biotech with a financial background. I really saw a cancer cell for the first time when my mom was diagnosed in 2007, a few months before my marriage. She is here with us today and she enjoys spending time her granddaughter, thanks to clinical research.”

He is a former VC, e.g. co-founder and CEO at Quantica SGR, Venture Consultant at Sofinnova Partners, co-founder and Investment Advisor at Axòn Capital, and co-founder and advisor at AurorA-TT. He is a board member of Italia Startup (Italian Association for startups) and Assobiotec (Italian Association of biotech companies). He is a member of Italian Angels for Biotech (business angel group) and Confindustria Life Sciences and Cluster Life Sciences – Lombardia.

Pierluigi Paracchi
Chairman and CEO



Carolyn R. “Bo” Aldigé

Founder and CEO at Prevent Cancer Foundation

Håkan Åström, Med.Dr.h.c.

Board member of Rhenman & Partners Asset Management, Karo Pharma AB and Chairman of the Board of PledPharma AB

Georges Garnier, MD

Head of Hematology and Oncology Department, Princess Grace Hospital, Monaco

David Hunt

CEO, Havas Lynx Group

Professor Patrick Rampal, MD

President, Scientific Center of Monaco

Stephen Squinto, PhD

Venture Partner at Orbimed, Co-Founder at Alexion, and Co-Founder & Chairman at Lyfebulb